Guía de Práctica Clínica sobre la Atención Integral a las Personas ...

cognitive drug research computerised assessment system. Dement GeriatrCogn Disord. 2002; 13(3): 183-92.205. Yaffe K, Fox P, Newcomer R, Sands L, Lindquist K, Dane K, et al.Patient and caregiver characteristics and nursing home placement inpatients with dementia. JAMA. 2002; 287(16): 2090-7.206. Edwards K, Royall D, Hershey L, Lichter D, Hake A, Farlow M, et al.Efficacy and safety of galantamine in patients with dementia withLewy bodies: a 24-week open-label study. Dement Geriatr Cogn Disord.2007; 23(6): 401-5.207. Molloy S, McKeith IG, O’Brien JT, Burn DJ. The role of levodopa inthe management of dementia with Lewy bodies. J Neurol NeurosurgPsychiatry. 2005; 76(9): 1200-3.208. Goldman JG, Goetz CG, Brandabur M, Sanfilippo M, Stebbins GT.Effects of dopaminergic medications on psychosis and motor functionin dementia with Lewy bodies. Mov Disord. 2008; 23(15): 2248-50.209. Boxer AL, Boeve BF. Frontotemporal dementia treatment: currentsymptomatic therapies and implications of recent genetic, biochemical,and neuroimaging studies. Alzheimer Dis Assoc Disord. 2007; 21(4):S79-S87.210. Méndez MF, Shapira JS, McMurtray A, Licht E. Preliminary findings:behavioral worsening on donepezil in patients with frontotemporal dementia.Am J Geriatr Psychiatry. 2007; 15(1): 84-7.211. Vossel KA, Miller BL. New approaches to the treatment of frontotemporallobar degeneration. Curr Opin Neurol. 2008; 21(6): 708-16.212. Aguilar M, Román G, Black S. Efficacy and safety of donepezil in vasculardementia: results from largest double-blind trial in vascular dementia.Proceedings of the 10th International Conference on Alzheimer’sDisease and Related Disorders. Madrid. 15-20 julio 2006. p. 4-439.213. Black S, Román GC, Geldmacher DS, Salloway S, Hecker J, Burns A,et al. Efficacy and tolerability of donepezil in vascular dementia: positiveresults of a 24-week, multicenter, international, randomized, placebo-controlledclinical trial. Stroke. 2003; 34(10): 2323-30.214. Wilkinson D, Doody R, Helme R, Taubman K, Mintzer J, Kertesz A,et al. Donepezil in vascular dementia: a randomized, placebo-controlledstudy. Neurology. 2003; 61(4): 479-86.215. Dichgans M, Markus HS, Salloway S, Verkkoniemi A, Moline M,Wang Q, et al. Donepezil in patients with subcortical vascular cognitiveimpairment: a randomised double-blind trial in CADASIL. LancetNeurol. 2008; 7(4): 310-8.216. Auchus A, Brashear H, Salloway S, Korczyn A, De Deyn P, Gassmann-Mayer C, et al. Galantamine treatment of vascular dementia: a randomizedtrial. Neurology. 2007; 69(5): 448-58.GUÍA DE PRÁCTICA CLÍNICA SOBRE LA ATENCIÓN INTEGRAL A LAS PERSONASCON ENFERMEDAD DE ALZHEIMER Y OTRAS DEMENCIAS309